Perrigo
PRGOMarket price data through November 10, 2026.
Performance
Nov 2021 – Nov 2026
Track record
How this pick has done since Benson first called it.
- Benson Return
- +24%
- How much this stock is up since Benson first picked it — measured from the price at the time of that first pick, not from today.
- First pick price
- ~$14
- Roughly what one share cost when Benson first picked this stock. This is the starting line for the Benson Return.
- Tracking since
- September 2026
- The month this stock first became a Benson pick.
- Tracking duration
- 2 months
- How long Benson has been tracking this pick.
About Perrigo
Perrigo makes the store brand version of the medicine you already buy, like the generic allergy pill or pain reliever sitting right next to the name brand at Walmart or CVS. It also owns its own brands, like the Opill birth control pill and Compeed blister bandages, and brings in close to 1 billion dollars in sales every quarter.
The case for and against
Both sides of the story, in plain English.
- Gaining Shelf Share
Shoppers bought less medicine, but Perrigo still won more of the market in U.S. store brand medicine and its key European brands. Its go forward business brought in 908 million dollars, down just 1.7 percent, and its women's health products grew strongly thanks to the ellaOne morning after pill and the Opill birth control pill. When money gets tight, people switch to cheaper store brands, and Perrigo is the one making them.
- Slimmer, Simpler Perrigo
Perrigo agreed to sell its infant formula business for up to 175 million dollars. That business saw sales fall 9.6 percent and lost money this quarter. Dropping it should lift profit margins and cut future factory spending, and Perrigo is also looking at what to do with its oral care business. Meanwhile, the company still paid shareholders 40 million dollars in dividends this quarter.
- Lowered Expectations
Total sales fell 5.2 percent to 989 million dollars, and adjusted profit dropped 25 percent to 60 cents a share. Management also lowered its outlook for the go forward business. It now expects sales to shrink 2.5 to 3.6 percent this year and profit of 2.15 to 2.35 dollars a share, down from 2.25 to 2.55 dollars before. Stores are ordering cold and flu medicine carefully, and shoppers in Europe are still spending less.
- Debt Still Dominates
Perrigo carries 3.3 billion dollars in debt against just 437 million dollars in cash, about 4 times its yearly cash profits. Selling the infant formula business will also mean another write down of 275 to 375 million dollars before the year ends. And an interim CEO is still running the company.
Other companies we track
How to read this page
This automated research summary uses Financial Modeling Prep market data through 2026-11-10. Model signals, scores, and risk labels can change and may be incomplete or wrong.
Want Benson to watch PRGO for you?
Get the app to follow every Benson pick live — and let Benson do the research for you.